BRPI0608376A8 - composição de ligação, método de uso de uma composição de ligação, e, kit de detecção - Google Patents

composição de ligação, método de uso de uma composição de ligação, e, kit de detecção

Info

Publication number
BRPI0608376A8
BRPI0608376A8 BRPI0608376A BRPI0608376A BRPI0608376A8 BR PI0608376 A8 BRPI0608376 A8 BR PI0608376A8 BR PI0608376 A BRPI0608376 A BR PI0608376A BR PI0608376 A BRPI0608376 A BR PI0608376A BR PI0608376 A8 BRPI0608376 A8 BR PI0608376A8
Authority
BR
Brazil
Prior art keywords
binding composition
detection kit
binding
composition
compositions
Prior art date
Application number
BRPI0608376A
Other languages
English (en)
Portuguese (pt)
Inventor
Edward Jones Bryan
Matthew Marquis David
Duane Dickinson Graig
Dean Watkins Jeffry
Davies Julian
Huang Lihua
Edward Vaillancourt Peter
William Rowlinson Scott
Tang Ying
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0608376A2 publication Critical patent/BRPI0608376A2/pt
Publication of BRPI0608376A8 publication Critical patent/BRPI0608376A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
BRPI0608376A 2005-04-22 2006-04-20 composição de ligação, método de uso de uma composição de ligação, e, kit de detecção BRPI0608376A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67408205P 2005-04-22 2005-04-22
US60/674082 2005-04-22
PCT/US2006/014943 WO2006116002A2 (en) 2005-04-22 2006-04-20 Tgf beta 1 specific antibodies

Publications (2)

Publication Number Publication Date
BRPI0608376A2 BRPI0608376A2 (pt) 2010-11-16
BRPI0608376A8 true BRPI0608376A8 (pt) 2018-10-16

Family

ID=37192643

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608376A BRPI0608376A8 (pt) 2005-04-22 2006-04-20 composição de ligação, método de uso de uma composição de ligação, e, kit de detecção

Country Status (23)

Country Link
US (2) US7619069B2 (https=)
EP (1) EP1874818B1 (https=)
JP (1) JP5070200B2 (https=)
KR (1) KR100978684B1 (https=)
CN (1) CN101163719A (https=)
AT (1) ATE505489T1 (https=)
AU (1) AU2006240056B2 (https=)
BR (1) BRPI0608376A8 (https=)
CA (1) CA2607448C (https=)
CY (1) CY1111518T1 (https=)
DE (1) DE602006021292D1 (https=)
DK (1) DK1874818T3 (https=)
EA (1) EA016038B1 (https=)
ES (1) ES2361269T3 (https=)
HR (1) HRP20110334T1 (https=)
IL (1) IL186775A (https=)
NO (1) NO20076003L (https=)
PL (1) PL1874818T3 (https=)
PT (1) PT1874818E (https=)
RS (1) RS51845B (https=)
SI (1) SI1874818T1 (https=)
UA (1) UA93201C2 (https=)
WO (1) WO2006116002A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102316898A (zh) * 2008-09-29 2012-01-11 森托科尔奥索生物科技公司 抗cd147抗体、方法和用途
MX2011005379A (es) * 2008-11-22 2011-06-09 Astute Medical Inc Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
US8685932B2 (en) * 2008-12-16 2014-04-01 Option Pharmaceuticals, Llc Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases
WO2010081004A1 (en) 2009-01-09 2010-07-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
WO2012129330A1 (en) 2011-03-23 2012-09-27 Option Pharmaceutical, Llc Targeted cytokine for treatment of musculoskeletal diseases
CN103732623B (zh) * 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
US9518112B2 (en) 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
CA2866378A1 (en) 2012-03-08 2013-09-12 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
MX387323B (es) * 2014-02-19 2025-03-18 Merck Patent Gmbh Il-12 dirigida al cáncer en combinación con il-7 para usarse en el tratamiento de cáncer.
WO2016115345A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
AU2017219254B2 (en) 2016-02-17 2019-12-12 Novartis Ag TGFbeta 2 antibodies
EP3420088A4 (en) * 2016-02-26 2019-10-30 The University of Western Ontario ANTI-CD11D ANTIBODIES AND USES THEREOF
CA3055555A1 (en) * 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgf.beta.1-binding immunoglobulins and use thereof
AU2017268234A1 (en) 2016-05-17 2018-12-13 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
MX2018014256A (es) * 2016-05-20 2019-08-16 Harvard College Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
TW201811827A (zh) * 2016-09-05 2018-04-01 日商中外製藥股份有限公司 抗ＴＧＦ－β１抗體及使用方法
WO2018128939A1 (en) 2017-01-05 2018-07-12 Gensun Biopharma Inc. Checkpoint regulator antagonists
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
WO2019045086A1 (ja) * 2017-08-29 2019-03-07 林化成株式会社 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
TW201923089A (zh) 2017-11-06 2019-06-16 美商建南德克公司 癌症之診斷及治療方法
US10597453B2 (en) 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
CN113677711B (zh) 2019-01-30 2025-05-30 供石公司 TGFβ的LTBP复合特异性抑制剂及其用途
CN114340735B (zh) 2019-06-28 2024-11-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
TW202135862A (zh) 2020-01-11 2021-10-01 美商供石公司 TGFβ抑制劑及其用途
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
KR20240022608A (ko) * 2021-06-18 2024-02-20 젠자임 코포레이션 항-tgf-베타 항체 제형 및 이의 용도
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
EP4599088A1 (en) 2022-10-05 2025-08-13 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
AU771635B2 (en) * 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7763580B2 (en) * 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
JP2006525362A (ja) * 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
MXPA06014067A (es) 2004-06-04 2007-02-15 Genentech Inc Metodo para tratar lupus.
WO2007041635A2 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties

Also Published As

Publication number Publication date
US20080050375A1 (en) 2008-02-28
SI1874818T1 (sl) 2011-08-31
IL186775A (en) 2013-03-24
US8128927B2 (en) 2012-03-06
PT1874818E (pt) 2011-05-05
WO2006116002A2 (en) 2006-11-02
PL1874818T3 (pl) 2011-09-30
NO20076003L (no) 2008-01-22
EP1874818B1 (en) 2011-04-13
KR100978684B1 (ko) 2010-08-31
US20100040633A1 (en) 2010-02-18
EA016038B1 (ru) 2012-01-30
CY1111518T1 (el) 2015-08-05
ES2361269T3 (es) 2011-06-15
WO2006116002A9 (en) 2007-07-19
IL186775A0 (en) 2008-02-09
AU2006240056B2 (en) 2012-02-16
US7619069B2 (en) 2009-11-17
EA200702278A1 (ru) 2008-08-29
JP2008538564A (ja) 2008-10-30
EP1874818A2 (en) 2008-01-09
HRP20110334T1 (hr) 2011-06-30
UA93201C2 (ru) 2011-01-25
BRPI0608376A2 (pt) 2010-11-16
CA2607448A1 (en) 2006-11-02
JP5070200B2 (ja) 2012-11-07
DK1874818T3 (da) 2011-06-14
KR20070114220A (ko) 2007-11-29
ATE505489T1 (de) 2011-04-15
CN101163719A (zh) 2008-04-16
AU2006240056A1 (en) 2006-11-02
DE602006021292D1 (de) 2011-05-26
CA2607448C (en) 2014-11-18
WO2006116002A3 (en) 2007-02-01
RS51845B (sr) 2012-02-29

Similar Documents

Publication Publication Date Title
BRPI0608376A8 (pt) composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
WO2007086904A3 (en) Compositions for use in identification of adenoviruses
WO2006116127A3 (en) Compositions for use in identification of bacteria
WO2006094238A3 (en) Compositions for use in identification of adventitious viruses
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
WO2007118222A3 (en) Compositions for the use in identification of fungi
MY163480A (en) Sclerostin binding agents
MY174493A (en) Binding agents
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EP2460828A3 (en) Antibodies and diagnostics
HUE042561T2 (hu) Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
EP1799260A4 (en) ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, TECHNIQUES AND USES
WO2008118626A3 (en) Inhibitors of jnk and methods for identifying inhibitors of jnk
NO20081287A (no) Brenselsammensetning og fremgangsmåte for å fremstille denne
AR059445A1 (es) Composiciones de antimicoticos ramnolipidicos y metodos de uso relacionados
BRPI0617479A2 (pt) método e composição útil para manter ou melhorar a saúde gastrintestiinal de um animal, kit, meio para comunicação de informações ou instruções, e, uso de uma composição
EP1836214A4 (en) COMPOSITIONS, METHODS, AND KITS FOR IMPROVING PROTEIN EXPRESSION, SOLUBILITY, AND ISOLATION
BRPI0606506A2 (pt) polipeptìdeos de yersinia spp. e métodos de uso
DE602006013151D1 (de) Verfahren zur herstellung von polymermaleimiden
WO2008127839A3 (en) Compositions for use in identification of bacteria
MX2007013470A (es) Forma purificada de tanaproget.
EP1938781A4 (en) DENTAL VULCANIZABLE COMPOSITION AND KIT FOR SUCH A VULCANIZABLE DENTAL COMPOSITION
ATE478950T1 (de) Verfahren und zusammensetzungen zum nachweis von immunantworten

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2510 DE 12-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.